Title : Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade.

Pub. Date : 2016

PMID : 27429741






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Vandetanib and cabozantinib, both multi-kinase inhibitors with RET activity, are approved for use in medullary thyroid carcinoma, but additional pharmacological activities, most notably inhibition of vascular endothelial growth factor - VEGFR2 (KDR), lead to dose-limiting toxicity. vandetanib kinase insert domain receptor Homo sapiens
2 Vandetanib and cabozantinib, both multi-kinase inhibitors with RET activity, are approved for use in medullary thyroid carcinoma, but additional pharmacological activities, most notably inhibition of vascular endothelial growth factor - VEGFR2 (KDR), lead to dose-limiting toxicity. vandetanib kinase insert domain receptor Homo sapiens